文献速递自身炎症与 IgG4 相关病其他结缔组织病

VEXAS综合征与癌症:国际AIDA注册研究提示癌症风险增加

VEXAS syndrome and cancer: Insights about a possible "Tip of the Iceberg". Ambidirectional data from the international AIDA network registries.
PubMed 文献 · Semin Arthritis Rheum · 2026-01-22

基于国际AIDA网络注册数据的双向研究,比较VEXAS综合征患者与Still病、白塞病及Schnitzler综合征对照者的癌症相对风险。在年龄>60岁人群中,VEXAS患者总体癌症相对风险为1.93(95%CI 1.03-3.60,p=0.036)。复发多软骨炎、p.Met41Thr突变及持续系统性炎症与癌症发生相关。

要点

  • VEXAS患者总体癌症风险较对照增加,RR=1.93(95%CI 1.03-3.60,p=0.036)。
  • 复发多软骨炎、p.Met41Thr突变、ESR和LDH升高与癌症发生相关。
  • 研究提示VEXAS患者需关注血液及非血液系统恶性肿瘤筛查。

核心结论

  • VEXAS患者血液及非血液系统恶性肿瘤风险较对照显著增加,尤其伴复发多软骨炎、p.Met41Thr突变及持续系统性炎症者。

研究设计与样本

  • 研究基于国际AIDA网络VEXAS、Still病、白塞病和Schnitzler综合征注册数据,采用双向设计比较癌症相对风险。

主要发现

  • VEXAS患者总体癌症相对风险为1.93(95%CI 1.03-3.60,p=0.036)。
  • 癌症发生与复发多软骨炎相关(RR=2.67,95%CI 1.22-10.64,p=0.01)。
  • 癌症发生与p.Met41Thr突变相关(RR=3.33,95%CI 1.29-17.33,p=0.02)。
  • 非 flare 期血沉升高与癌症发生相关(RR=1.02,95%CI 1.01-1.05,p=0.01)。
  • 非 flare 期乳酸脱氢酶升高与癌症发生相关(RR=1.02,95%CI 1.01-1.07,p=0.04)。

临床怎么用

  • 对VEXAS患者应提高癌症警惕,尤其合并复发多软骨炎、p.Met41Thr突变或非 flare 期ESR/LDH持续升高者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome is an acquired autoinflammatory disorder characterized by severe chronic inflammation and an increased occurrence of hematologic neoplasms. Although chronic inflammation is a well-established risk factor for cancer, the specific contribution of UBA1 gene mutations to tumorigenesis remains unclear. Therefore, this study aimed to evaluate the overall cancer risk in patients with VEXAS syndrome, including both hematologic and non-hematologic neoplasms. METHODS: The relative risk (RR) of cancer was compared between VEXAS patients and a control cohort comprising individuals with Still's disease, Behçet's disease, and Schnitzler's syndrome. Logistic regression analysis was performed to identify variables potentially associated with cancer development. Patient's data were drawn from the International AutoInflammatory Disease Alliance (AIDA) Network registries for VEXAS syndrome, Still's disease, Behçet's disease, and Schnitzler's syndrome. RESULTS: Ninety-six VEXAS patients and 2181 controls were enrolled. To minimize selection bias, only subjects aged >60 years were included, yielding 90 and 174 individuals in the exposed and control groups, respectively. The overall RR for cancer in VEXAS patients was 1.93 (95 % Confidence Interval [C.I.] 1.03-3.60, p = 0.036). Logistic regression analysis identified associations between cancer development and relapsing polychondritis (RR = 2.67, 95 %C.I. 1.22-10.64, p = 0.01), the p.Met41Thr mutation (RR = 3.33, 95 %C.I. 1.29-17.33, p = 0.02), elevated serum erythrocyte sedimentation rate (RR = 1.02, 95 %C.I. 1.01-1.05 p = 0.01), and lactate dehydrogenase (RR = 1.02, 95 %C.I. 1.01-1.07 p = 0.04) levels outside of flares. CONCLUSIONS: VEXAS patients exhibit a significantly increased risk of both hematologic and non-hematologic malignancies compared with controls, particularly among those with RP, p.Met41Thr mutation, and persistent systemic inflammation.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Gavioli F, Caggiano V, Sbalchiero J, et al. VEXAS syndrome and cancer: Insights about a possible "Tip of the Iceberg". Ambidirectional data from the international AIDA network registries. Semin Arthritis Rheum. 2026. PMID: 41619570. doi:10.1016/j.semarthrit.2026.152932

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。